| Results | Differences (Gains) | ||||
---|---|---|---|---|---|---|
 | No vaccination (NV) | Quadrivalent (QV) | Bivalent (BV) | QV - NV | BV - NV | BV-QV |
A: Health outcomes and disease-related costs | ||||||
Undiscounted | ||||||
 LYs | 18,351,285 | 18,395,244 | 18,398,735 | 43,959 | 47,451 | 3,491 |
 QALYs | 18,337,584 | 18,390,430 | 18,393,973 | 52,845 | 56,389 | 3,544 |
 Cervical cancer cases | 7,398 | 2,967 | 2,616 | −4,431 | −4,781 | −350 |
 Cervical cancer deaths | 3,701 | 1,558 | 1,391 | −2,143 | −2,310 | −168 |
 Genital Warts (new and recurrent) | 21,025 | 2,566 | 21,025 | −18,459 | 0 | 18,459 |
 Total cost other than vaccinationa | 11,295.9 VEF | 7,109.9 VEF | 7,107.3 VEF | −4,186.0 VEF | −4,188.6 VEF | −2.6 VEF |
  Costs of screening | 4,323.0 VEF | 4,396.1 VEF | 4,383.3 VEF | 73.1 VEF | 60.3 VEF | −12.8 VEF |
  Costs of CIN 1 | 601.4 VEF | 303.3 VEF | 344.9 VEF | −298.1 VEF | −256.5 VEF | 41.5 VEF |
  Costs of CIN 2/3 | 262.3 VEF | 122.7 VEF | 102.6 VEF | −139.6 VEF | −159.7 VEF | −20.1 VEF |
  Costs of warts | 309.2 VEF | 37.7 VEF | 309.3 VEF | −271.4 VEF | 0.1 VEF | 271.6 VEF |
  Costs of cancer | 5,800.1 VEF | 2,250.1 VEF | 1,967.3 VEF | −3,550.0 VEF | −3,832.7 VEF | −282.7 VEF |
 Discounted (5%) | ||||||
 LYs | 5,277,952 | 5,281,034 | 5,281,282 | 3,082 | 3,330 | 248 |
 QALYs | 5,276,066 | 5,280,461 | 5,280,552 | 4,395 | 4,486 | 91 |
 Total cost other than vaccinationa | 2,435.2 VEF | 1,602.7 VEF | 1,672.5 VEF | −832.6 VEF | −762.8 VEF | 69.8 VEF |
  Costs of screening | 1,130.3 VEF | 1,151.9 VEF | 1,148.5 VEF | 21.6 VEF | 18.2 VEF | −3.5 VEF |
  Costs of CIN 1 | 167.1 VEF | 82.8 VEF | 91.8 VEF | −84.3 VEF | −75.4 VEF | 9.0 VEF |
  Costs of CIN 2/3 | 79.5 VEF | 35.2 VEF | 28.6 VEF | −44.3 VEF | −50.9 VEF | −6.6 VEF |
  Costs of warts | 136.7 VEF | 16.7 VEF | 136.7 VEF | −120.0 VEF | 0.0 VEF | 120.0 VEF |
  Costs of cancer | 921.6 VEF | 316.0 VEF | 266.9 VEF | −605.6 VEF | −654.7 VEF | −49.1 VEF |
B: Vaccine costs per scenarioa | Â | Â | Â | Â | Â | Â |
 2: Both vaccines = 8.5 US$; 2-dose scheme - FX 6.3 | 0 VEF | 26.9 VEF | 26.9 VEF | 26.9 VEF | 26.9 VEF | 0 VEF |
 4: Both vaccines = 8.5 US$; 2-dose scheme - FX: 170 | 0 VEF | 726.2 VEF | 726.2 VEF | 726.2 VEF | 726.2 VEF | 0 VEF |
 6: BV: 8.5 US$ QV: 13.79 US$; 2-dose scheme - FX 6.3 | 0 VEF | 43.7 VEF | 26.9 VEF | 43.7 VEF | 26.9 VEF | −16.7 VEF |
 8: BV: 8.5 US$ QV: 13.79 US$; 2-dose scheme - FX: 170 | 0 VEF | 1,178.1 VEF | 726.2 VEF | 1,178.1 VEF | 726.2 VEF | −451.9 VEF |